Abbott first warned the public about this problem in November. Now, for the second time in less than a month, the FDA is providing additional details. 

“This is not about alarming people,” one researcher said. “It’s about recognizing an environmental factor that may be contributing to high blood pressure in some communities and making sure it’s part of the public health conversation." 

Cannabis use has been linked to multiple cardiovascular risks, but less is known about how it may affect patients who undergo major cardiac surgery.

Abbott pointed to double-digit growth for its Navitor TAVR valve as well as big gains for the TriClip and MitraClip devices. The company also shared positive sales figures for its EP, heart failure and rhythm management portfolios. 

The diet, named after the traditional eating habits of Greece and Italy, is already known for its benefits to the general public. Its impact on heart patients, however, was less clear. 

The FDA finalized four Class I recalls related to safety concerns first reported by Abbott in November. Meanwhile, a Florida man who uses these sensors to manage his diabetes has already filed a lawsuit over the issue.

Medtronic's MiniMed Go technology was designed to deliver real-time health data and recommendations to patients with type 1 and type 2 diabetes. It works with the Instinct sensors designed by Abbott.

This product was distributed throughout the United States from April 2022 to December 2025. Customers have been warned to stop taking it immediately.